ClassID:

170624

G01N2333/91142 - CPC Classification

Classification description:

Assays involving biological materials from specific organisms or of a specific nature; Enzymes; Proenzymes; Transferases (2.); Glycosyltransferases (2.4) Pentosyltransferases (2.4.2)

Recent Application in this class:
#1
20260098867
2026-04-09

METAL NANOPARTICLE, AND PLASMONIC BIOSENSOR COMPRISING THE SAME

#2
20260048040
2026-02-19

MTA-COOPERATIVE PRMT5 INHIBITORS FOR USE IN THE TREATMENT OF CANCER

#3
20250093370
2025-03-20

BIOMARKERS AND THEIR USE IN DIAGNOSING PARKINSON'S DISEASE, VITREORETINAL DISEASES, AND AGE-RELATED PATHOLOGIES

#4
20250020654
2025-01-16

SCREENING METHODS FOR PARP MODULATORS

#5
20240252689
2024-08-01

POLY-ADP RIBOSE (PAR) TRACKER OPTIMIZED SPLIT-PROTEIN REASSEMBLY PAR DETECTION REAGENTS

#6
20240241113
2024-07-18

Method for detecting binding to an ADP-ribosyl group or a polymer thereof and a kit for performing said method

#7
20240159750
2024-05-16

METHODS FOR DIAGNOSIS AND TREATMENT OF COVID-19

#8
20240102994
2024-03-28

Method to Evaluate the Capability of Compounds on the Trapping of Proteins

#9
20230417767
2023-12-28

COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AGE-RELATED MACULAR DEGENERATION

#10
20220206008
2022-06-30

SCREENING METHODS FOR PARP MODULATORS

#11
20220017943
2022-01-20

FAMIN Assay Methods

#12
20210346322
2021-11-11

Compounds for use in the treatment of cancer

#13
20210072244
2021-03-11

METHODS AND COMPOSITIONS FOR TREATING MELANOMA RESISTANT

#14
20200157138
2020-05-21

NICOTINAMIDE ADENINE DINUCLEOTIDE ANALOGUES

#15
20200123192
2020-04-23

Compounds and methods used in assessing mono-PARP activity

#16
20200109156
2020-04-09

Radiolabeled and fluorescent PARP inhibitors for imaging and radiotherapy

#17
20190331688
2019-10-31

Screening methods for PARP modulators

#18
20190105289
2019-04-11

Compounds for use in the treatment of cancer

#19
20190049465
2019-02-14

COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AGE-RELATED MACULAR DEGENERATION

#20
20180275142
2018-09-27

Markers for inflammatory bowel disease

#21
20180223288
2018-08-09

COMPOSITIONS AND METHODS FOR THE MODULATION OF DNA DAMAGE RESPONSES USING BAL1 AND BBAP

#22
20180148764
2018-05-31

Enzymatic modification of nucleic acids

#23
20180024129
2018-01-25

Lateral flow device and method of use

#24
20170363633
2017-12-21

METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT

#25
20170307592
2017-10-26

Neuroprotective Chemicals and Methods for Identifying and Using Same

#26
20170205429
2017-07-20

Markers for inflammatory bowel disease

#27
20170160282
2017-06-08

Methods for breast cancer treatment

#28
20170146517
2017-05-25

COMPOUNDS AND METHODS USED IN ASSESSING MONO-PARP ACTIVITY

#29
20170030897
2017-02-02

Neuroprotective chemicals and methods for identifying and using same

#30
20160299141
2016-10-13

NAD analogs and methods of using said NAD analogs in determining ribosylation of proteins with PARP mutants

#31
20160287622
2016-10-06

COMPOSITIONS AND METHODS FOR TREATING IMMUNE AND VIRAL DISORDERS AND MODULATING PROTEIN-RNA INTERACTION

#32
20160274115
2016-09-22

NOVEL METHOD TO DETECT RESISTANCE TO CHEMOTHERAPY IN PATIENTS WITH LUNG CANCER

#33
20160223554
2016-08-04

METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT

#34
20160202262
2016-07-14

APTAMERS SCREENING METHOD BASED ON GRAPHENE WITHOUT TARGET IMMOBILIZATION AND THE APTAMERS OBTAINED FROM THE METHOD

#35
20160202259
2016-07-14

Aptamers screening method based on graphene without target immobilization and the aptamers obtained from the method

#36
20160144013
2016-05-26

Compositions and methods for diagnosing, preventing and treating and infection

#37
20160097083
2016-04-07

Screening assay for identification of poly(ADP-ribose) polymerase 1 inhibitors

#38
20160067305
2016-03-10

Lamin A, an activator of longevity/anti-aging SIRT1 protein

#39
20160010067
2016-01-14

NOVEL POLY(ADP-RIBOSE) POLYMERASE GENES

#40
20150355172
2015-12-10

ADP-ribose detection reagents

#41
20150337316
2015-11-26

Phosphoribosyl pyrophosphate synthetase 2 (PRPS2) as a therapeutic target in cancer treatment

#42
20150198597
2015-07-16

Method for monitoring PARP activity in cells by PARP activation

#43
20150020221
2015-01-15

Compositions and methods for the modulation of DNA damage responses using BAL1 and BBAP

#44
20130288367
2013-10-31

Cell culture model for acquired chemoresistance of chronic myelogenous leukemia and related methods for identifying agents to overcome resistance

#45
20130156776
2013-06-20

Compositions and methods for treating cancer and modulating stress granule formation

#46
20130029930
2013-01-31

Activation and activators of SirT6

#47
20130029362
2013-01-31

MARKERS AND ASSAYS FOR DETECTION OF NEUROTOXICITY

#48
20120277110
2012-11-01

PARP AND ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN NON-SMALL-CELL LUNG CANCER

#49
20120164670
2012-06-28

METHODS AND KITS FOR MEASURING ENZYME ACTIVITY

#50
20120077685
2012-03-29

INTRATUMORAL GENE EXPRESSION LEVELS OF TP AND VEGF ARE ASSOCIATED WITH CLINICAL OUTCOMES IN RECTAL CANCER PATIENTS TREATED WITH 5-FLUOROURACIL AND PELVIC RADIATION

#51
20110262943
2011-10-27

REAGENT KIT FOR MEASURING FRESHNESS

#52
20110176996
2011-07-21

Compositions and methods for cancer management using antibodies binding to nucleotide salvage pathway enzymes and complexes thereof

#53
20110171671
2011-07-14

Method for diagnosing acute cardiac ischemia

#54
20110130340
2011-06-02

Methods of identifying anti-cancer agents and uses thereof

#55
20110107444
2011-05-05

Poly(ADP-ribose) polymerase genes

#56
20110098190
2011-04-28

SIRT4 ACTIVITIES

#57
20110097329
2011-04-28

COMPOSITIONS AND METHODS FOR TREATING CANCER AND MODULATING STRESS GRANULE FORMATION

#58
20110092695
2011-04-21

Cell culture model for acquired chemoresistance of chronic myelogenous leukemia and related methods for identifying agents to overcome resistance

#59
20110065121
2011-03-17

METHOD FOR THE DETECTION OF APOPTOSIS

#60
20100330583
2010-12-30

Compositions and methods for identification of PARP function, inhibitors, and activators

#61
20100196909
2010-08-05

PARP-BASED CYTOCHEMICAL AND HISTOCHEMICAL DETECTION METHODS AND KITS THEREFORE

#62
20100008894
2010-01-14

Process of Screening a Molecule as a Candidate Drug for the Treatment of Bipolar Disorder

#63
20090263399
2009-10-22

Method for establishing the sensitivity of tumours to capecitabin and test kit

#64
20090208982
2009-08-20

ASSAY METHOD FOR HUMAN OROTATE PHOSPHORIBOSYLTRANSFERASE PROTEIN

#65
20090093458
2009-04-09

Methods of identifying anti-cancer agents and uses thereof

#66
20080113871
2008-05-15

Assays useful in determining CD38 inhibition

#67
20070275988
2007-11-29

Transition state structure and inhibitors of thymidine phosphorylases

#68
20070099830
2007-05-03

Sirt4 activities

#69
20060246459
2006-11-02

Ups as modifiers of the beta catenin pathway and methods of use

#70
20050204410
2005-09-15

SIRT6 transgenic non-human animals and assay methods

#71
20050142621
2005-06-30

Method of identifying compounds that induce cell death by necrosis